drugset / Trial / NCT02708914
Study to Compare the Safety and Efficacy of UB-851 and Eprex®
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to evaluate a 1:1 dose conversion from Eprex® to UB-851 in terms of clinical efficacy and safety in subjects with chronic renal failure receiving hemodialysis.
Timeline
- Start
- 2016-03
- Primary completion
- 2021-10
- Completion
- 2021-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UB-851 | Protein / enzyme biologic | — | Intravenous |
| Subject | epoetin alfa | Protein / enzyme biologic | — | Intravenous |